BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 32250059)

  • 1. Exposure-Response Analysis to Assess the Concentration-QTc Relationship of Psilocybin/Psilocin.
    Dahmane E; Hutson PR; Gobburu JVS
    Clin Pharmacol Drug Dev; 2021 Jan; 10(1):78-85. PubMed ID: 32250059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of Escalating Doses of Oral Psilocybin in Healthy Adults.
    Brown RT; Nicholas CR; Cozzi NV; Gassman MC; Cooper KM; Muller D; Thomas CD; Hetzel SJ; Henriquez KM; Ribaudo AS; Hutson PR
    Clin Pharmacokinet; 2017 Dec; 56(12):1543-1554. PubMed ID: 28353056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and validation of an LC-MS/MS method for the bioanalysis of psilocybin's main metabolites, psilocin and 4-hydroxyindole-3-acetic acid, in human plasma.
    Kolaczynska KE; Liechti ME; Duthaler U
    J Chromatogr B Analyt Technol Biomed Life Sci; 2021 Feb; 1164():122486. PubMed ID: 33485158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determination of psilocin and 4-hydroxyindole-3-acetic acid in plasma by HPLC-ECD and pharmacokinetic profiles of oral and intravenous psilocybin in man.
    Hasler F; Bourquin D; Brenneisen R; Bär T; Vollenweider FX
    Pharm Acta Helv; 1997 Jun; 72(3):175-84. PubMed ID: 9204776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitation of psilocin in human plasma by high-performance liquid chromatography and electrochemical detection: comparison of liquid-liquid extraction with automated on-line solid-phase extraction.
    Lindenblatt H; Krämer E; Holzmann-Erens P; Gouzoulis-Mayfrank E; Kovar KA
    J Chromatogr B Biomed Sci Appl; 1998 May; 709(2):255-63. PubMed ID: 9657222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolism of psilocybin and psilocin: clinical and forensic toxicological relevance.
    Dinis-Oliveira RJ
    Drug Metab Rev; 2017 Feb; 49(1):84-91. PubMed ID: 28074670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Approach to Evaluating QT Prolongation of Quetiapine Fumarate in Late Stage of Clinical Development Using Concentration-QTc Modeling and Simulation in Japanese Patients With Bipolar Disorder.
    Fukushi R; Nomura Y; Katashima M; Komatsu K; Sato Y; Takada A
    Clin Ther; 2020 Aug; 42(8):1483-1493.e1. PubMed ID: 32792252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High dose psilocybin is associated with positive subjective effects in healthy volunteers.
    Nicholas CR; Henriquez KM; Gassman MC; Cooper KM; Muller D; Hetzel S; Brown RT; Cozzi NV; Thomas C; Hutson PR
    J Psychopharmacol; 2018 Jul; 32(7):770-778. PubMed ID: 29945469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of olanzapine and samidorphan has no clinically relevant effects on ECG parameters, including the QTc interval: Results from a phase 1 QT/QTc study.
    Sun L; Yagoda S; Xue H; Brown R; Nangia N; McDonnell D; Rege B; von Moltke L; Darpo B
    Prog Neuropsychopharmacol Biol Psychiatry; 2020 Jun; 100():109881. PubMed ID: 32004636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized study of the effect of gadopiclenol, a new gadolinium-based contrast agent, on the QTc interval in healthy subjects.
    Funck-Brentano C; Felices M; Le Fur N; Dubourdieu C; Desché P; Vanhoutte F; Voiriot P
    Br J Clin Pharmacol; 2020 Nov; 86(11):2174-2181. PubMed ID: 32302009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of psilocin in body fluids.
    Sticht G; Käferstein H
    Forensic Sci Int; 2000 Sep; 113(1-3):403-7. PubMed ID: 10978655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels.
    Madsen MK; Fisher PM; Burmester D; Dyssegaard A; Stenbæk DS; Kristiansen S; Johansen SS; Lehel S; Linnet K; Svarer C; Erritzoe D; Ozenne B; Knudsen GM
    Neuropsychopharmacology; 2019 Jun; 44(7):1328-1334. PubMed ID: 30685771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Study to Assess the Proarrhythmic Potential of Mirtazapine Using Concentration-QTc (C-QTc) Analysis.
    Gurkan S; Liu F; Chain A; Gutstein DE
    Clin Pharmacol Drug Dev; 2019 May; 8(4):449-458. PubMed ID: 30052325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Olaparib does not cause clinically relevant QT/QTc interval prolongation in patients with advanced solid tumours: results from two phase I studies.
    Swaisland H; Plummer R; So K; Garnett S; Bannister W; Fabre MA; Dota C; Fielding A
    Cancer Chemother Pharmacol; 2016 Oct; 78(4):775-84. PubMed ID: 27553432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the Potential for QTc Prolongation With Repeated Oral Doses of Fedratinib in Patients With Advanced Solid Tumors.
    Ogasawara K; Xu C; Yin J; Darpo B; Carayannopoulos L; Xue H; Palmisano M; Krishna G
    Clin Pharmacol Drug Dev; 2021 Apr; 10(4):366-375. PubMed ID: 32673446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Randomized, Single-Blind, Placebo-Controlled, 3-Way Crossover Study to Evaluate the Effect of Therapeutic and Supratherapeutic Doses of Edaravone on QT/QTc Interval in Healthy Subjects.
    Shimizu H; Inoue S; Endo M; Nakamaru Y; Yoshida K; Natori T; Kakubari M; Akimoto M; Kondo K
    Clin Pharmacol Drug Dev; 2021 Jan; 10(1):46-56. PubMed ID: 32543120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Phase 1 Study of Intravenous Plazomicin in Healthy Adults to Assess Potential Effects on the QT/QTc Interval, Safety, and Pharmacokinetics.
    Gall J; Choi T; Riddle V; Van Wart S; Gibbons JA; Seroogy J
    Clin Pharmacol Drug Dev; 2019 Nov; 8(8):1032-1041. PubMed ID: 30650259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concentration-QTc modeling of sitravatinib in patients with advanced solid malignancies.
    Dickinson A; Liu Y; Uvarov A; Peyret T; Marier JF; Chin C; Tran JQ
    Clin Transl Sci; 2024 May; 17(5):e13808. PubMed ID: 38700272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the Effect of 5 QT-Positive Drugs on the JTpeak Interval - An Analysis of ECGs From the IQ-CSRC Study.
    Darpo B; Benson C; Brown R; Dota C; Ferber G; Ferry J; Jarugula V; Keirns J; Ortemann-Renon C; Pham T; Riley S; Sarapa N; Ticktin M; Zareba W; Couderc JP
    J Clin Pharmacol; 2020 Jan; 60(1):125-139. PubMed ID: 31378962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the Effect of Selumetinib on Cardiac Repolarization: A Randomized, Placebo- and Positive-controlled Crossover QT/QTc Study in Healthy Subjects.
    Zhou D; So K; Dymond AW; Vik T; Al-Huniti N; Mariani G; Zorenyi G; Huang Y; Holmes V; Severin P; Rasmussen S; Martin P
    Clin Ther; 2016 Dec; 38(12):2555-2566. PubMed ID: 27837934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.